Poster Category

AACR 2021: TNFR2 and PD-1/PD-L1/TNFR2 humanized mice aid exploration of combination strategies to overcome tumor immune escape mechanisms

Tumor necrosis factor receptor 2 (TNFR2), also known as tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), is a transmembrane protein, which can mediate both…

Read more
AACR 2021: Novel human B7-H3 knock-in mice demonstrate efficacy of anti-B7-H3 immunotherapy in vivo

In recent years, immune checkpoint inhibitors (ICIs), particularly against PD-1/PD-L1, have revolutionized cancer treatment. However, ICI monotherapy only benefits a portion of cancer patients, while…

Read more
AACR 2021: A novel humanized B-hPD-1/hPD-L1/hTIGIT mouse model reveals enhanced efficacy of combined TIGIT and PD-L1 blockade against cancer

Immune checkpoint blockade targeting PD-1/PD-L1 has enjoyed tremendous success in the clinic against various advanced stage cancers, unleashing potent and durable immune-mediated control of tumors…

Read more
AACR 2021: SIGLEC15 humanized knock-in mice are a powerful tool to evaluate new therapies for cancer and osteoporosis

SIGLEC15 (Sialic acid-binding immunoglobulin-like lectin 15) belongs to the Siglec family of sialic acid-binding, immunoglobulin-like proteins. SIGLEC15 is an effective immunosuppressive molecule that is highly…

Read more
AACR 2021: Advancing Bispecific Antibody Discovery using a Common Light Chain Immunoglobulin Humanized Mouse

The common challenges of bispecific therapeutic antibody discovery are immunogenicity and chain mispairing issues. Biocytogen’s RenLiteTM immunoglobulin humanized mouse is designed not only to overcome…

Read more
AACR 2021: A Novel PD1-CD40 Bispecific Antibody YH008 Induces Potent Anti-tumor Activity in-vivo by PD1 Dependent Activation of CD40 Signaling

Immunotherapies that target PD1/PDL1 pathway have marked a new era of cancer therapy. Combinatorial treatment of inhibiting PD1/PDL1 signaling and other immunomodulating agents has been…

Read more
AACR 2020: In vivo drug screening platform accelerates anti-hCD40 antibody drug discovery

The CD40 (also known as TNFRSF5) and its ligand CD40L (also known as CD154) belong to the TNF/TNFR family. CD40 is expressed on antigen presenting…

Read more
AACR 2020: Novel TNFR2 humanized mouse model for human TNFR2 antibody evaluation

In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Tumor necrosis factor receptor 2 (TNFR2), also known as tumor necrosis factor receptor superfamily…

Read more
AACR 2020: Evaluating anti-IL-2Ra in vivo efficacy on humanized knock-in mice

Interleukin-2 receptor alpha chain (also called as CD25) is a 55 kD glycoprotein, also known as IL-2Ra, Ly-43, p55, or Tac. It is expressed on activated…

Read more
AACR 2020: Rapid screening of novel OX40 agonistic antibodies for cancer immunotherapy

OX40, also known as TNFRSF4 or CD134, is a member of the tumor necrosis factor receptor superfamily and is an important co-stimulator of T cell…

Read more
Back to top